Infectious Disease of LungNCT04629222
Tracheobronchitis in Respiratory Involvement on the Lung SPECT/CT Images of Coronavirus Disease (COVID-19) Patients
An observational study of Infectious Disease of Lung, run by Central Hospital, Nancy, France at 1 site in France.
Trial summary
Tracheobronchitis signs may be observed on ventilation lung scintigraphy during coronavirus disease (COVID-19) infection. This case report study aimed to analyze the rates and associated factors of such tracheobronchitis in COVID-19 patients referred to ventilation/perfusion lung scintigraphy with shortness of breath… Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Infectious Disease of Lung
- How many people
- 10 participants
- Where
- 1 siteFrance
- Study dates
- 11 Mar 2020to 23 Jul 2020
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: patients experiencing shortness of breath during the course of a COVID-19
Who may be able to join
- patient with Tracheobronchitis signs
- patient with lung scintigraphy exam
Who cannot join
- none
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Tracheobronchitis May Constitute the Main Sign of Respiratory Involvement on the Lung SPECT/CT Images of COVID-19 Patients
Tracheobronchitis signs may be observed on ventilation lung scintigraphy during coronavirus disease (COVID-19) infection. This case report study aimed to analyze the rates and associated factors of such tracheobronchitis in COVID-19 patients referred to ventilation/perfusion lung scintigraphy with shortness of breath, suspected of pulmonary embolism.
Read the detailed description
It was a retrospective study
- Conditions
- Infectious Disease of Lung
- Keywords
- Coronavirus Disease (COVID-19), Lung ventilation, Perfusion scintigraphy, Tracheobronchitis, Shortness of breath, Cadmium-Zinc-Telluride (CZT)-SPECT, Computer Tomography (CT)
- Medical subject headings
- COVID-19, Dyspnea
What is being measured
The primary outcome is the main question the study is designed to answer.
Tracheobronchitis signs may be observed on ventilation lung scintigraphy during COVID-19 infection.
analyze the rates and associated factors of such tracheobronchitis in COVID-19 patients referred to ventilation/perfusion lung scintigraphy with shortness of breath, suspected of pulmonary embolism.
Measured: 1 month
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Nov 2020
- Study start11 Mar 2020
- Primary completion20 Jul 2020
- Study completion23 Jul 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Infectious Disease of LungStudies of the same condition, open and under way.
- More trials run by Central Hospital, Nancy, FranceThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Retrospective
- Enrolment
- 10 participants (actual)
Sponsor and investigators
- Lead sponsor
- Central Hospital, Nancy, France
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Pierre Yves MARIE, Central Hospital, Nancy, France
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04629222
- Sponsor's protocol ID
- 2020PI154
- Status last verified
- Jun 2024
- First submitted
- 13 Nov 2020
- Last updated
- 21 Jun 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 21 Jun 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Tracheobronchitis May Constitute the Main Sign of Respiratory Involvement on the Lung SPECT/CT Images of COVID-19 Patients
- ClinicalTrials.gov ID
- NCT04629222
- Acronym / sponsor ID
- 2020PI154
- Conditions
- Infectious Disease of Lung
- Keywords
- Coronavirus Disease (COVID-19), Lung ventilation, Perfusion scintigraphy, Tracheobronchitis, Shortness of breath, Cadmium-Zinc-Telluride (CZT)-SPECT, Computer Tomography (CT)
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 10 participants (actual)
- Lead sponsor
- Central Hospital, Nancy, FranceUniversity, hospital or other
- Study start
- 11 Mar 2020 (actual)
- Primary completion
- 20 Jul 2020 (actual)
- Study completion
- 23 Jul 2020 (actual)
- First posted
- 16 Nov 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Tracheobronchitis signs may be observed on ventilation lung scintigraphy during coronavirus disease (COVID-19) infection. This case report study aimed to analyze the rates and associated factors of such tracheobronchitis in COVID-19 patients referred to ventilation/perfusion lung scintigraphy with shortness of breath, suspected of pulmonary embolism.
Detailed description
It was a retrospective study
Study design
- Observational model
- Case-control
- Time perspective
- Retrospective
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- patients experiencing shortness of breath during the course of a COVID-19
Key inclusion criteria (2 listed)
- patient with Tracheobronchitis signs
- patient with lung scintigraphy exam
Key exclusion criteria (1 listed)
- none
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Tracheobronchitis signs may be observed on ventilation lung scintigraphy during COVID-19 infection.
Time frame: 1 month
analyze the rates and associated factors of such tracheobronchitis in COVID-19 patients referred to ventilation/perfusion lung scintigraphy with shortness of breath, suspected of pulmonary embolism.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Jun 2024.
Related trials for Infectious Disease of Lung
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
RecruitingObservational study
VIRal Pulmonary Infections in Older AGE
Viral Pulmonary Infections
Not yet recruitingPhase 2/3
A Pivotal Safety and Immunogenicity GBS-NN/NN2 Vaccine Maternal Immunisation Trial
Streptococcus Agalactiae Infection, Neonatal Sepsis
Not yet recruiting
Expanded Diagnostic Strategy in Older Adults Hospitalized With Community-Acquired Acute Respiratory Infection
Acute Respiratory Infection
RecruitingObservational study
Cardiovascular Disease Progression in Survivors of Community Acquired Pneumonia and Lung Infection by Covid-19.
Pneumonia, Community-Acquired, COVID-19 Pneumonia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Infectious Disease of Lung, run by Central Hospital, Nancy, France at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 21 Jun 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Tracheobronchitis signs may be observed on ventilation lung scintigraphy during COVID-19 infection. (time frame: 1 month). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Jun 2024.